COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS

摘要

The present invention relates to a novel medical use of selective CB1 receptor antagonistic compounds in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The CB1 receptor antagonistic compounds suitable according to the invention are elucidated in more detail in the description. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.